These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36997080)

  • 21. Psychedelic Microdosing: A Subreddit Analysis.
    Lea T; Amada N; Jungaberle H
    J Psychoactive Drugs; 2020; 52(2):101-112. PubMed ID: 31648596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers.
    Li H; Zhong Y; Yang S; Wang J; Li X; Xu J; Gao H; Chen G
    Hum Psychopharmacol; 2022 May; 37(3):e2825. PubMed ID: 34739739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
    Polito V; Liknaitzky P
    J Psychopharmacol; 2024 Aug; 38(8):701-711. PubMed ID: 38877715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
    Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
    J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the 5-HT
    Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX
    J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
    Pouyan N; Younesi Sisi F; Kargar A; Scheidegger M; McIntyre RS; Morrow JD
    CNS Drugs; 2023 Dec; 37(12):1027-1063. PubMed ID: 37999867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
    Kaertner LS; Steinborn MB; Kettner H; Spriggs MJ; Roseman L; Buchborn T; Balaet M; Timmermann C; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2021 Jan; 11(1):1941. PubMed ID: 33479342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
    Glazer J; Murray CH; Nusslock R; Lee R; de Wit H
    Neuropsychopharmacology; 2023 Jan; 48(2):418-426. PubMed ID: 36284231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
    Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
    Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inter-individual variability in neural response to low doses of LSD.
    Hutten NRPW; Quaedflieg CWEM; Mason NL; Theunissen EL; Liechti ME; Duthaler U; Kuypers KPC; Bonnelle V; Feilding A; Ramaekers JG
    Transl Psychiatry; 2024 Jul; 14(1):288. PubMed ID: 39009578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety pharmacology of acute LSD administration in healthy subjects.
    Holze F; Caluori TV; Vizeli P; Liechti ME
    Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
    Kaypak AC; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):665-674. PubMed ID: 36031848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
    Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
    Elife; 2018 Oct; 7():. PubMed ID: 30355445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
    Lo DF; Zia H; Rajkumar P; Thakur A; O'Donnell H
    Prim Care Companion CNS Disord; 2024 Jan; 26(1):. PubMed ID: 38228068
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
    Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Forsyth A; Bansal M; Muthukumaraswamy S
    Pilot Feasibility Stud; 2023 Oct; 9(1):169. PubMed ID: 37798662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.